IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Grüllich, C.; Motzer, R. J.; Powles, T.; Atkins, M.; Escudier, B. J.; McDermott, D.; Suarez, C.; Bracarda, S.; Stadler, W.; Donskov, F.; Lee, J. L.; Hawkins, R.; Ravaud, A.; Alekseev, B.; Staehler, M.; Uemura, M.; Donaldson, F.; Li, S.; Huseni, M.; Schiff, C.; Rini, B. I. |
| Abstract Title: | IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 41 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2018 Sep 28-Oct 2 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2018-09-01 |
| Start Page: | 41 |
| End Page: | 42 |
| Language: | English |
| ACCESSION: | WOS:000446816500106 |
| PROVIDER: | wos |
| PUBMED: | 30261496 |
| DOI: | 10.1159/000492737 |
| Notes: | Meeting Abstract: V165 -- Source: Wos |
